ATL-024 / Antelope Therapeutics - LARVOL DELTA

ATL-024, a novel topoisomerase I-based ADC targeting the tumor-specific glycopepitope CA242 (CanAg), demonstrates potent activity in colorectal and pancreatic cancer models, and excellent safety profile (AACR 2026) - "Pharmacokinetic profiling showed linear dose-dependent exposure and is consistent with systemic stability of the conjugate.Overall, the preclinical characterization of ATL-024 shows a very favorable therapeutic index and support human clinical evaluation for patients with CA242-expressing gastrointestinal tumors such as colorectal or pancreatic tumors. ATL-024 is currently undergoing IND-enabling development."

ADC • Clinical • Preclinical • Colorectal Cancer • Gastric Cancer • Oncology • Pancreatic Cancer • Solid Tumor • TOP1